Chasing the alpha
It’s time to switch horses again and turn our attention to the final ASCO Plenary series of the year with another look at an anti-TIGIT trial.
After all the attention on the Genentech/Roche CITYSCAPE and SKYSCRAPER trials evaluating tiragolumab plus atezolizumab in combination of late, this time around it’s the turn of Arcus and Gilead to be in the hot seat.
In this latest instance they have data from a three arm open label randomised phase 2 study (ARC-7) exploring the Fc silent anti-TIGIT antibody domvanalimab plus zimberelimab, with and without their adenosine axis therapy, etrumadenant, both compared with the anti-PD-1 antibody alone in 1L NSCLC.
The results turned out to be rather controversial for a number of reasons, so let’s take a deeper look at what can be learned and why it matters…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
